France · Delayed Price · Currency is EUR Transgene Company Description
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors.
The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial.
It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen.
The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
| Country | France |
| Founded | 1979 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Alessandro Riva |
Contact Details
Address: 400, boulevard Gonthier d’Andernach Illkirch-Graffenstaden, 67405 France | |
| Phone | 33 3 88 27 91 00 |
| Website | transgene.com |
Stock Details
| Ticker Symbol | TNG |
| Exchange | Euronext Paris |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0005175080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Alessandro Riva M.D. | Chief Executive Officer and Chairman of the Board |
| Lucie Larguier | Vice President and Chief Financial Officer |
| Dr. Simone Silva Steiner Ph.D. | Chief Technical Officer |
| Dr. Maurizio Ceppi | Chief Scientific Officer |
| John Felitti J.D., LLM | Vice President, General Counsel and Corporate Secretary |
| Christelle Schwoerer | Chief Human Resources Officer |
| James Wentworth M.B.A., Ph.D. | Vice President and Chief Business Officer |
| Emmanuelle Dochy M.D. | Vice President of Medical Affairs and Chief Medical Officer |
| Katell Bidet Huang | Head of Translational Medicine |
| Feriel Marin | Interim Chief Quality Officer |